| Not Yet Recruiting | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel NCT07200089 | Washington University School of Medicine | Phase 1 |
| Not Yet Recruiting | Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma NCT07456605 | University Health Network, Toronto | Phase 1 |
| Not Yet Recruiting | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm NCT07421856 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778 | CellCentric Ltd. | Phase 2 |
| Recruiting | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager NCT07094048 | CHU de Quebec-Universite Laval | Phase 4 |
| Not Yet Recruiting | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma NCT06880601 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Not Yet Recruiting | BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma NCT07196124 | Guangzhou Bio-gene Technology Co., Ltd | EARLY_Phase 1 |
| Not Yet Recruiting | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma NCT06698744 | David Wald | Phase 1 |
| Recruiting | HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM NCT06822972 | Duke University | Phase 2 |
| Enrolling By Invitation | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients NCT07210047 | HuniLife Biotechnology, Inc. | Phase 1 / Phase 2 |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma NCT07032129 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Universal CAR-T Cell Therapy for MM NCT07248176 | Bioray Laboratories | N/A |
| Recruiting | Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma NCT07477912 | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Phase 1 / Phase 2 |
| Withdrawn | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multipl NCT06411301 | Jules Bordet Institute | Phase 1 |
| Recruiting | A Trial of Selinexor, Ruxolitinib and Methylprednisolone NCT06225310 | Oncotherapeutics | Phase 1 |
| Recruiting | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma NCT06485076 | University Health Network, Toronto | N/A |
| Recruiting | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myelom NCT06115135 | Oncotherapeutics | Phase 2 |
| Not Yet Recruiting | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma NCT06242249 | Shahid Beheshti University of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | LMY-920 for Treatment of Relapsed or Refractory Myeloma NCT05546723 | Luminary Therapeutics | Phase 1 |
| Withdrawn | Marizomib Central Nervous System (CNS) NCT05050305 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting NCT05836896 | Technische Universität Dresden | Phase 1 |
| Recruiting | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple My NCT06158412 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Not Yet Recruiting | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM NCT05909826 | Dong-A University Hospital | Phase 2 |
| Unknown | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT05749133 | XuYan | Phase 1 / Phase 2 |
| Active Not Recruiting | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma NCT05673083 | All4Cure | — |
| Unknown | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT05739188 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Withdrawn | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. NCT05493618 | Hackensack Meridian Health | Phase 1 / Phase 2 |
| Completed | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; th NCT05555329 | Amsterdam UMC, location VUmc | Phase 4 |
| Unknown | Long-term KRd in Relapsed and/or Refractory Multiple Myeloma NCT05495620 | Dong-A University Hospital | — |
| Terminated | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participa NCT05121103 | Epizyme, Inc. | Phase 1 |
| Terminated | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies NCT05191472 | Alfred Chung, MD | Phase 2 |
| Recruiting | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma NCT04657861 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma NCT05008536 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Unknown | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma NCT04861480 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients NCT04688853 | Gadeta B.V. | Phase 1 |
| Completed | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carf NCT04813653 | Tel-Aviv Sourasky Medical Center | Phase 1 |
| Recruiting | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignan NCT04603872 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Rel NCT04287855 | Poitiers University Hospital | Phase 2 |
| Recruiting | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and NCT04414475 | Karyopharm Therapeutics Inc | Phase 2 |
| Completed | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment NCT04811898 | Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Phase 1 |
| Completed | Alvocade® (Bortezomib) Safety and Effectiveness Study NCT06012383 | NanoAlvand | — |
| Completed | Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT02176213 | Ajai Chari | Phase 2 |